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Abstract
To determine effects of cryptococcal meningitis (CM) on human immunodeficiency virus (HIV)-1C cerebrospinal fluid (CSF) viral
escape, CSF/plasma viral discordance, and drug resistance mutation (DRM) discordance between CSF and plasma compartments,
we compared CSF and plasma viral load (VL) and DRMs in individuals with HIV-associated CM in Botswana.
This cross-sectional study utilized 45 paired CSF/plasma samples from participants in a CM treatment trial (2014–2016). HIV-1 VL
was determined and HIV-1 protease and reverse transcriptase genotyping performed. DRMs were determined using the Stanford
HIV database. CSF viral escape was defined as HIV-1 ribonucleic acid ≥0.5 log10 higher in CSF than plasma and VL discordance as
CSF VL > plasma VL.
HIV-1 VL was successfully measured in 39/45 pairs, with insufficient sample volume in 6; 34/39 (87.2%) participants had
detectable HIV-1 in plasma and CSF, median 5.1 (interquartile range: 4.7–5.7) and 4.6 (interquartile range:3.7–4.9) log10copies/mL,
respectively (P.001). CSF viral escape was present in 1/34 (2.9%) and VL discordance in 6/34 (17.6%). Discordance was not
associated with CD4 count, antiretroviral status, fungal burden, CSF lymphocyte percentage nor mental status. Twenty-six of 45
(57.8%) CSF/plasma pairs were successfully sequenced. HIV-1 DRM discordance was found in 3/26 (11.5%); 1 had I84IT and
another had M46MI in CSF only. The third had K101E in plasma and V106M in CSF.
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Our findings suggest that HIV-1 escape and DRMdiscordancemay occur at lower rates in participants with advanced HIV-disease
and CM compared to those with HIV associated neurocognitive impairment.
Abbreviations: AMBITION-cm = ambisome therapy induction optimisation for Cryptococcal Meningitis, aOR = adjusted odds
ratio, ART = antiretroviral therapy, ARV = antiretroviral drugs, BBB = blood brain barrier, CM = cryptococcal meningitis, CNS =
central nervous system, CSF = cerebrospinal fluid, DRM = drug resistance mutations, HIV = human immunodeficiency virus, PCR =
polymerase chain reaction, RNA = ribonucleic acid, RT = reverse transcriptase, VL = viral load.
Keywords: cerebrospinal fluid, compartmentalisation, cryptococcal meningitis, drug resistance mutations, human immunodefi-
ciency virus, viral escape
1. Introduction
Successful roll-out of antiretroviral therapy (ART) has signifi-
cantly reduced morbidity, mortality and incidence of opportu-
nistic infections associatedwithHuman ImmunodeficiencyVirus
(HIV) infection and acquired immune deficiency syndrome.[1]
However, Sub-Saharan Africa continues to be disproportionate-
ly burdened by the HIV-1 epidemic and the region has the
greatest number of deaths, morbidity, and opportunistic
infections.[2] One of the major biological barriers to complete
eradication of HIV-1 is the ability of the virus to compartmen-
talise in reservoir sites such as the central nervous system (CNS),
lymphoid tissue, gut tissues, and other anatomical sites.[3] The
CNS can serve as a sanctuary for HIV-1 replication resulting in
persistent infection, emergence of drug resistance mutations
(DRM), and the development of HIV-associated neurocognitive
disorders.[4]
After HIV-1 seeds to the CNS, compartmentalisation and
replication in the CNS may yield elevated cerebrospinal fluid
(CSF) HIV-1 ribonucleic acid (RNA) despite undetectable or low
viral loads (VL) in the plasma, a phenomena commonly known
as CSF viral escape or discordance.[5,6] The global prevalence
of CSF viral escape is reported to be between 0.7% and 27.4%.[7]
Factors such as low nadir CD4 count, ART treatment
interruptions, persistent low level viremia and poor penetration
of some antiretroviral drugs (ARV) through the blood brain
barrier (BBB) into the CNS contribute to CSF viral escape.[8,9] In
addition, discordant DRMs in the CSF and plasma can influence
the development of CSF HIV-1 viral escape and limit future
effectiveness of ARVs.[5,10] Furthermore, sub-optimal penetra-
tion by some ARVs into certain anatomical sites can lead to
decreased therapeutic drug levels in the CSF thus promoting
development of DRMs.[11]
One of the major causes of acquired immune deficiency
syndrome-related morbidity and mortality is HIV-associated
cryptococcal meningitis (CM).[12] There are still conflicting
data relating to effects of CM on CSF HIV-1 VL. It has been
suggested that CM causes an inflammation of the meninges
that allows leucocytes harbouring HIV-1 to enter CNS leading
to an increased HIV-1 VL.[13] However, a direct association
between high CM burden and high HIV-1 VL has not been
shown.[13,14] Furthermore, there are no data regarding
discordant DRMs in the context of HIV-associated CM, which
may be of clinical and public health relevance given the
increasing proportion of CM patients who are now ART-
experienced.[15,16]
To address these knowledge gaps, the aim of this study was to
investigate HIV-1C CSF viral escape and VL discordance as well
as DRM discordance between CSF and plasma compartments
among people living with HIV-associated CM.
2. Materials and methods
2.1. Study design
A retrospective cross-sectional study utilizing archived samples
and existing patient data from the “AMBIsome Therapy
Induction OptimisatioN for Cryptococcal Meningitis” (AMBI-
TION-cm) study was performed. AMBITION-cm was a multi-
site phase-II non-inferiority trial which aimed to investigate the
early fungicidal activity of 3 short-course, high-dose liposomal
amphotericin regimens for CM. The trial recruited 80 partic-
ipants across 2 sites: Princess Marina Hospital (Gaborone,
Botswana) and Bugando Medical Centre and Seko Toure
Hospital (Mwanza, Tanzania) between October 2014 and
September 2016.[16]
2.2. Study population
We tested archived CSF and plasma samples from AMBITION-
cm participants recruited in Gaborone, Botswana. All AMBI-
TION-cm participants were confirmed to have HIV by a rapid
diagnostic test prior to enrolment or evidence of a previously
documented positive test or detectable HIV-1 VL. CM infection
was determined by positive India Ink or cryptococcal antigen in
CSF. We used samples collected on study day 3 or 7 depending
on their availability; 45 participants had paired CSF and
plasma samples available and were subsequently included in
this study.
2.3. Ethics
The study was approved by the University of Botswana
Institutional Review Board and a research permit was obtained
from Botswana Ministry of Health and Wellness (HPDME:13/
18/1). All participants had previously consented to the use of their
stored samples in future research into the pathophysiology of
HIV-associated CM in the parent study (ISRCTN#10248064).
2.4. Laboratory investigations
2.4.1. HIV-1 Viral Load Assay. CSF samples were centrifuged at
1200xg for 10 minutes in order to obtain cell-free supernatant.
HIV-1 VL was measured in plasma and CSF using Abbott
m2000rt/m2000sp assay (Abbott Laboratories, Abbott Park,
Illinois, U.S.A). Samples with volumes below 800mLwere diluted
with phosphate buffered saline in a 1:5 ratio and the resulting VL
multiplied by the dilution factor as per manufacturer’s
instructions. CSF viral escape was defined as HIV-1 VL ≥
0.5log10copies/mL higher in CSF than plasma VL while CSF/
Plasma HIV-1 VL discordance was defined as any CSF HIV-1 VL
greater than plasma VL as previously described.[5,17]
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2.4.2. RNA extraction.HIV-1 RNA was extracted from 140mL
of plasma and CSF supernatant using QIAamp RNA extraction
mini kit (Qiagen, Hilden, Germany) according to the manu-
facturer’s instructions.
2.5. Amplification of the pol gene
Complementary DNA from protease and reverse transcriptase
(RT) of the HIV-1 pol gene was synthesized in a one-step
polymerase chain reaction (PCR) using transcriptor 1-step PCR
kit (Roche Applied Science, Germany) as previously described.[18]
Phusion High Fidelity DNA Polymerase PCR protocol (New
England Biolabs, Hitchin, UK) was used for second round
PCR according to the manufacturer’s instructions. The primers
used contained equal volumes of 2mM forward (LNAF1; 5’-
GAAGGACCAAATGAAAGAYTG-3’) and 2.5mM reverse
primer (RT20C; 5’-CTGCCAATTCTAACTGCTTC-3’). Second
round amplicons were loaded on a 1% agarose gel in Tris-Borate-
ethylenediaminetetraacetic acid (TBE) buffer and run at 100V for
45 minutes in order to check amplification success.
2.6. Sanger sequencing
Following purification of the second-round amplicons, sequenc-
ing PCR was done using Big Dye Terminator sequencing kit
according to the manufacturer’s protocol (Applied Biosystems,
Foster City, CA). The 7 primers used for sequencing were as
previously described.[18] These were designed such that atleast 2
primers overlap at any given position of the amplicon. The
sequences generated were then purified using ZR DNA
sequencing clean-up kit (Zymo Research, CA) then determined
on the ABI Prism 3130xl genetic analyzer (Applied Biosystems,
Foster City, CA).
2.7. Phylogenetic analyses
Raw sequences were edited manually using Sequencher
software version 5.0 (Gene codes Corporation, Ann Arbor,
MI). To identify HIV-1 DRMs, the consensus sequences
were analysed in the Stanford HIV Drug Resistance Database.
The consensus sequences were aligned with HIV-1 HXB2 and
subtype reference sequences from Los Alamos National
Laboratory HIV database in Bioedit version 7 software.
Neighbour-joining phylogenetic tree was constructed in MEGA
version 7 software with 1000 bootstrap replicates to check for
contamination and relatedness (Substitution model: Tamura-2-
parameter, T92+G+I). All HIV-1 sequences described in this
study were submitted to Genbank (accession numbers:
MT663164-MT663215).
2.8. Statistical analysis
Wilcoxon signed rank test was used to compare paired CSF and
plasma HIV-1 VL. Spearman rank correlation was used to assess
the correlation between CSF and plasma VL. Fisher’s exact test or
logistic regression was used to analyse categorical data where
appropriate. Factors associated with CSF/ plasma HIV-1 VL
discordance and mental status were determined using binary
logistic regression. To adjust for confounders, multivariable
analysis with covariates selected a priori was performed. P-
values< .05 were considered to be statistically significant. All
analyses were performed using R version 3.6.0.[19]
3. Results
3.1. Participants characteristics
The participants enrolled in the AMBITION-cm study in
Botswana from whom samples were obtained were predomi-
nantly male 28/45 (62.2%) and the median age was 38 (Q1,
Q3: 32–44) years. The baseline median CD4+ T-cell count was
28 (Q1, Q3: 10–46) cells/uL and 12/45 (26.7%) participants
were on ART, mostly Tenofovir Disoproxil Fumarate,
Emtricitabine and Efavirenz (tenofovir disoproxil fumarate/
emtricitabine / efavirenz) regimen. A total of 13/45 (28.8%)
participants had an abnormal mental status at baseline and the
overall median CSF fungal burden as determined by quantita-
tive cryptococcal culture was 5.0 (Q1, Q3: 3.7–5.6) log10cells/
mL (Table 1).
3.2. Relationship between CSF and Plasma HIV-1 VL
Among 45CSF/plasma paired samples available, 39 pairs were
tested for VL and 6 pairs were excluded due to insufficient
volumes (Fig. 1). A total of 34/39 participants (87.2%) had
detectable HIV-1 VL in plasma and CSF with medians of 5.1
(interquartile range: 4.8–5.7) and 4.6 (interquartile range: 3.8–
4.9) log10copies/mL, respectively (P< .001) (Fig. 2A). There was
a weak positive linear relationship between the CSF and plasma
HIV-1 VL (Spearman r= .5218, P= .002) (Fig. 2B).
3.3. CSF viral escape and CSF HIV-1 VL discordance
CSF HIV-1 viral escape was observed in 1/34 (2.9%) [95% CI:
0.07–15.30]. The participant was ART naïve with median HIV-1
VL of 5.0 (5.0–5.0) and 6.0 (6.0–6.0) log10copies/mL in plasma
and CSF, respectively. This individual had an abnormal mental
status and died before the end of the trial.
HIV-1 VL discordance was observed in 6/34 (17.6%) pairs.
Discordance was not associated with CD4+ T-cell count, protein
and glucose concentration, age, fungal burden, CSF lymphocytes
percentage or ART status (Table 2). No correlation was observed
between CSF HIV-1 VL and fungal burden (Spearman r=0.06,
P= .71, protein concentration (Spearman r=0.16, P= .35),
lymphocyte percentage (Spearman r= -0.06, P= .80) or CD4+
T-cell count (Spearman r=0.07, P= .67).
3.4. Association between CSF/Plasma HIV-1 VL
discordance and mental status
Participants who had HIV-1 VL discordance had 7-fold higher
odds of abnormal mental status than those who were non-
discordant (P= .04). However, after adjusting for fungal
burden, CSF HIV-1 VL, ART status and CD4+ T-cell count,
this did not reach statistical significance (adjusted odds ratio
(aOR)=7.88, 95% confidence intervals (CI)=0.75–83.4, P
= .09) (See Table 1, Supplemental content 1, http://links.lww.
com/MD/E974, which illustrates predictors of mental status in
participants with HIV-associated Cryptococcal Meningitis).
Median CSF HIV-1 VL was higher in participants with
abnormal mental status than those with normal mental status
reaching borderline statistically significance (P= .05). However,
CSF HIV-1 VL and ART status were not predictors of mental
status in the adjusted analysis (aOR=2.07 per log10 increase in
VL, 95% CI=0.49–8.68, P= .32; and on ART aOR=1.56,
95% CI=0.07–37.5, P= .78).
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3.5. HIV-1 Pol drug resistance associated mutations
All the 45 participants had CSF/plasma paired samples available
for genotyping and 34 plasma and 32 CSF samples were
successfully genotyped. However, only 26 were paired CSF/
plasma samples (See Figure, Supplemental content 2, http://links.
lww.com/MD/E978, which shows a Neighbour-joining phyloge-
netic tree generated from HIV-1C protease and RT sequences of
26 CSF and plasma paired samples.). Of the 26 pairs, 5
participants had HIV-1 strains with DRMs. The most predomi-
nant mutation was K101E, occurring in HIV-1 strains of 2
plasma samples and in 1 CSF sample. All other mutations
occurred at an equal frequency of 1 in plasma and CSF (Table 3).
HIV-1 DRM discordance was present in 3/26 (12%) HIV-1
strains of the paired samples. Of these, one had HIV-1 strain
harbouring I84IT and the other had M46MI protease inhibitor
(PI)-associated mutation in CSF but not in the plasma. The third
participant had HIV-1 strain with RTmutation K101E in plasma
and V106M in CSF.
4. Discussion
In this cross-sectional study evaluating HIV-1 VL and DRM
discordance between CSF and plasma in participants with HIV-
associated CM, we identified only 1 case (2.9%) of CSF viral
escape. We reported 17.6% of cases to have CSF/plasma HIV-1
VL discordance. HIV-1 VL was significantly higher in plasma
than CSF and a weak positive linear relationship was observed
between the 2 compartments. Those with CSF/plasma HIV-1 VL
discordance had higher odds of abnormal mental status, although
this did not reach statistical significance, and with only 1 case of
CSF viral escape, we could not assess whether mental status was
associated CSF viral escape.
HIV-1 VL discordance and CSF HIV-1 VL was not associated
with either CD4+ T-cell count, CSF protein and glucose
concentration, CSF lymphocytes percentage, CSF white cell
count or fungal burden in our patient population. Increased CSF
leucocyte counts and lower peripheral CD4+ T cell counts have
Table 1
Baseline characteristics and demographics of the 45 study
participants.
Patient characteristics (N=45)
Median age, yr (IQR) 38 (32, 44)
Gender
Male (%) 28 (62)
Female (%) 17 (38)
Median CD4 count, cells/ mL (IQR) 28 (10–46)
On ART or previously exposed, n (%)
Yes 12 (27)
No 33 (73)
Duration on ART, months (IQR) 5 (1–45)
ART regimen, n=12, (%)
TDF/FTC/EFV 6 (50)
TDF/FTC/NVP 2 (16.7)
ABC/FTC/RAL 1 (8.3)
ABC/FTC/EFV 1 (8.3)
AZT/FTC/EFV 1 (8.3)
TDF/FTC/DTG 1 (8.3)
Mental status, n (%)
Normal 32 (71)
Abnormal 13 (29)
CSF glucose concentrations, mmol (IQR) 2.4 (1.9–3.1)
CSF Protein concentrations, mg/dL (IQR) 0.9 (0.5–1.9)
CSF WBC, cells/ mL (IQR) 10 (3.0–53.0)
Median Fungal burden, log10 CFU/mL (IQR) 5.0 (3.7–5.6)
ABC= abacavir; ART= antiretroviral therapy; AZT= zidovudine; CSF= cerebrospinal fluid; DTG=
dolutegravir; EFV= efavirenz; FTC= emtricitabine; IQR= (interquartile anges; 25th percentile and
75th percentile); NVP=nevirapine; RAL= raltegravir; TDF= tenofovir Disoproxil Fumarate; WBC=
white blood cell Count.
Figure 1. Consort diagram showing enrolment criteria, study design and study population.
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previously been found to correlate with CSF HIV-1 viral burden
and escape in participants with either neurocognitive disorders or
CM presumably as HIV-1 may cross the BBB via infected cells
contributing to higher HIV-1 VL in the CNS.[13,20–24] A lack of
correlation between CSF lymphocyte count and CSF HIV-1 VL
may suggest that CNS occurs as a distinct compartment from
peripheral blood and can support HIV replication or that
replication occurs in different cell types in the CNS.[24]
A lack of association between CSF/plasma HIV-1 VL
discordance, CSF HIV-1 VL and CM fungal burden in our
study corroborate findings from other studies which reported
that high CM burden does not contribute to elevated CSF HIV-1
VL.[13,14] Some studies have reported absence of CSF viral escape
at the time of CM and neurological impairment and 23.1%HIV-
1 VL discordance.[14] This may suggest that HIV-associated CM
does not necessarily predispose to CSF viral escape. We could not
assess the impact of ART exposure on HIV-1 VL discordance as
all participants with HIV-1 VL discordance were ART naïve.
In a univariable analysis model, participants with HIV-1 VL
discordance had 7-fold higher odds of abnormal mental status.
However, after adjusting for fungal burden, CSFHIV-1 VL, ART
status and CD4+ T-cell count, the relationship was not
statistically significant, perhaps reflecting our small sample size.
Studies show that CSF/plasma HIV-1 discordance or escape is a
Figure 2. (A) Comparison of median HIV–1 viral load in plasma and Cerebrospinal fluid (CSF) paired samples, n=34. (B) The relationship between Cerebrospinal
fluid (CSF) and plasma HIV-1 viral load, n=34.
Table 2
Factors associated Cerebrospinal Fluid and plasma HIV-1 VL discordance.
Discordant (n=6) Non-discordant (n=28) OR (95% CI) (Unadjusted) P-value (Univariable)
Median Fungal burden, log10 CFU/mL (IQR) 5.7 (5.2–6.4) 5.0 (4.1–5.7) 2.13 (0.76–5.91) .15
Median age
<45 5 (83.3%) 21 (75.0%) 1.00 (ref) .66
≥45 1 (16.7%) 7 (25.0%) 0.60 (0.06–6.05)
Gender
Male 5 (83.3%) 17 (60.7%) 1.00 (ref) .31
Female 1 (16.7%) 11 (39.3%) 0.31 (0.03–3.01)
CD4, cells/ mL
≥100 1 (16.7%) 4 (14.3%) 1.00 (ref) .91
<100 5 (83.3%) 23 (82.1%) 0.87 (0.08–9.54)
ART status
Naïve (%) 6(100%) 21 (75%) 1.00 (ref) .65
Experienced (%) 0 7 (25%) 0.58 (0.06–5.83)
CSF lymphocyte %, cells/ mL
≥50 5 (83.3%) 9 (32.1%) 1.00 (ref) .70
<50 0 1 (3.6%) 1.80 (0.09–35.4)
CSF protein concentration, mg/dL
≥1 4 (66.7%) 11 (39.3%) 1.00 (ref) .26
<1 2 (33.3%) 16 (57.1%) 0.34 (0.05–2.21)
CSF glucose concentration, mmol
≥2 2 (33.3%) 17 (60.7%) 1.00 (ref) .17
<2 4 (66.7%) 9 (32.1%) 3.78 (0.58–24.75)
CSF WBC, cells/mm3
≥20 4 (66.7%) 9 (32.1%) 1.00 (ref) 1.00
<20 1 (16.7%) 16 (57.1%) 0.14 (0.01–1.46)
ART=antiretroviral Therapy; CSF= cerebrospinal fluid; IQR= (Interquartile ranges; 25th percentile and 75th percentile); OR=odds ratios; Ref= reference; VL= viral load; WBC=white blood cell count.
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predictor of neurocognitive disorder, however, these studies have
evaluated effects of CSF viral escape on progressive neuro-
cognitive disorders whereas our study focused mainly on
pathogenic neurological infection in the CNS and the relatively
low number of participants with discordance, may have
overshadowed our ability to determine the impact of a slightly
higher CSF HIV-1 VL on cognitive function.[17,25]
Among 5 participants harbouring drug resistant HIV-1 strains,
3 had DRM discordance. In 1 participant, NNRTI mutations
K101E and V106M were observed in plasma and CSF
compartment, respectively. Two ART naïve participants had
HIV-1 strain harbouring PI-associated DRMs in their CSF and
not in plasma. One participant had M46MI mutation and the
other had I84IT. Although there is discordance in thesemutations
between the CSF and plasma, according to the StanfordHIV drug
resistance database, M46MI only confers resistance PI only when
present with other mutation while I84T is not known to produce
resistance to PI.[26] These mutations occur at lower frequency in
ART naïve participants but it was not possible to determine if
their presence is due to transmitted drug resistance or the
undisclosed ART status.[26–28] If these participants were
previously exposed to PIs then occurrence of these mutations
solely in the CSF compartment would be attributable to low CNS
penetration effectiveness of PIs via the BBB.[6,29,30] In all these
participants with HIV-1 DRM discordance, there was no
evidence of viral escape as a result of present DRMs. One
patient harboured HIV-1 strain with extensive DRMs and high
HIV-1 VL in both CSF and plasma (patient ID:1736, Table 3).
Inability of the participant to achieve suppressed HIV-1 VL even
after 110 months of ART could be attributable to poor ART
adherence resulting in development of DRMs.
One of the limitations of this study is that most studies define
viral discordance as HIV-1 VL ≥ 0.5 or 1 log10copies/mL in CSF
as compared to plasma, but we defined HIV-1 VL discordance as
any CSF VL higher than plasma VL and this may have
implications on the clinical significance of the results obtained.
A lack of a control group, that is, HIV infected individuals
without CM was a limiting factor because HIV-associated CM
can lead to secondary escape which is not necessarily due to
compartmentalization but presence of pathogenic neurological
infection such as CM. Studies with ultra-deep sequencing are
warranted for the detection of HIV minority variants in the 2
compartments which may be missed by population sequencing.
Despite the limitations, this is the first known study in Botswana
to report on HIV-1C genetic discordance in CSF and plasma
compartments of participants with HIV-associated CM.
In conclusion, low rates of CSF viral escape were observed in
participants with HIV-associated CM in Botswana. We observed
discordant DRMs between compartments. Further evaluation of
HIV-1 viral factors that mediate CSF viral escape and HIV-1
DRM discordance may be important in understanding clinical
implications in participants with HIV-associated CM.
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Table 3
Characteristics of participants with HIV-1 Protease and Reverse transcriptase associated mutations in cerebrospinal fluid and plasma.
Plasma DRM CSF DRM
ID
Age
(yr)
ART
regimen
Duration
on ART
(mo)
CD4
count
(cells/uL) Mortality
Mental
status
Plasma
VL log10
(copies/mL)
CSF VL
log10
(copies/mL) NRTI NNRTI PI NRTI NNRTI PI
1930 27 ART naïve N/A 40 No N 6.37 4.94 None None None None None I84IT
1736 42 TDF/FTC/EFV 110 2 No N 5.80 4.74 D67N,
K70G,
M184V,
K219E
K101E,
K103N,
E138A,
G190A
None D67N,
K70G,
M184V,
K219E
K101E,
K103N,
E138A,
G190A
None
1134 37 ABC/FTC/EFV 3 222 No N 4.05 2.76 None K101E None None V106M None
1895 62 ART naïve N/A 16 Yes A 4.79 4.82 None None None None None M46MI
1528 61 TDF/FTC/NVP 87 158 Yes A 5.28 4.92 M184MI None None M184MI None None
ABC= abacavir; A=abnormal mental status; ART= antiretroviral therapy; CSF= cerebrospinal fluid; DRM=drug resistance mutations; EFV=efavirenz; FTC= emtricitabine; N=normal mental status; N/A=
data not available; NNRTI=non-nucleoside reverse transcriptase inhibitors; None=no major drug resistance mutations; NVP = nevirapine, NRTI=nucleoside reverse transcriptase inhibitors; PI=protease
inhibitors; TDF = tenofovir disoproxil fumarate, VL= viral load; Mutations in bold are discordant between the CSF and plasma compartment.
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